Antimicrobial Therapeutics Reviews
Antibiotics that Target the Ribosome, Volume 1241
Annals of the New York Academy of Sciences
1. Edition June 2012
179 Pages, Softcover
Wiley & Sons Ltd
This second installment of Antimicrobial Therapeutics
Reviews presents scholarly reviews on several key areas in the
field of antimicrobial therapeutics, including several papers on
issues relating to antibiotics that target the ribosome.
Topics covered include plasmid-encoded resistance determinants for
agents that bind the ribosome, new compound classes targeting the
ribosome, sequence-specific action of antibiotics binding the
ribosome, smFRET approaches to determine MOA of antibiotics binding
to the ribosome, new approaches for treating Staphylococcus biofilm
infections, and the history of tetracyclins. The volume also
features reviews dealing with drug development, such as
pleuromutilin discovery and development challenges and an update on
newer oxazolidinones such as torezolid and radezolid, and a review
on regulatory hurdles for new antibiotics.
NOTE: Annals volumes are available for sale as individual
books or as a journal. For information on institutional journal
subscriptions, please visit href="http://ordering.onlinelibrary.wiley.com/subs.asp?ref=1749-6632&doi=10.1111/(ISSN)1749-6632">http://ordering.onlinelibrary.wiley.com/subs.asp?ref=1749-6632&doi=10.1111/(ISSN)1749-6632.
ACADEMY MEMBERS: Please contact the New York Academy of Sciences
directly to place your order (href="http://www.nyas.org">www.nyas.org). Members of the New
York Academy of Science receive full-text access to Annals
online and discounts on print volumes. Please visit href="http://www.nyas.org/MemberCenter/Join.aspx">http://www.nyas.org/MemberCenter/Join.aspx
for more information about becoming a member.
On the specificity of antibiotics targeting the large ribosomal subunit
The history of the tetracyclines
Macrolide antibiotics in the ribosome exit tunnel : species-specific binding and action
The oxazolidinones : past, present, and future
Are pleuromutilin antibiotics finally fit for human use?
Plasmid-mediated resistance to protein biosynthesis inhibitors in staphylococci
New approaches for treating staphylococcal biofilm infections
Antibiotics in development targeting protein synthesis
Understanding the regulatory hurdles for antibacterial drug development in the post-Ketek world
Aureomycin : a product of the continuing search for new antibiotics